T&L Co., Ltd. (KOSDAQ:340570)
43,550
-350 (-0.80%)
At close: Jan 19, 2026
T&L Co., Ltd. Revenue
T&L Co., Ltd. had revenue of 40.67B KRW in the quarter ending September 30, 2025, a decrease of -16.52%. This brings the company's revenue in the last twelve months to 177.27B, up 17.93% year-over-year. In the year 2024, T&L Co., Ltd. had annual revenue of 174.89B with 51.47% growth.
Revenue (ttm)
177.27B
Revenue Growth
+17.93%
P/S Ratio
1.98
Revenue / Employee
732.53M
Employees
242
Market Cap
351.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 174.89B | 59.43B | 51.47% |
| Dec 31, 2023 | 115.46B | 33.88B | 41.54% |
| Dec 31, 2022 | 81.58B | 9.68B | 13.47% |
| Dec 31, 2021 | 71.90B | 31.26B | 76.94% |
| Dec 31, 2020 | 40.63B | 8.01B | 24.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |